Isro ex-engineers launch A'bad into space race
Ahmedabad's space technology sector is breaking new frontiers with startups founded by former Isro engineers collectively raising $5.3 million (Rs 45 crore), positioning the city as a serious contender in India's commercial space race.
SatLeo Labs recently closed a $3.3 million (Rs 28 crore) pre-seed funding round led by Merak Ventures, with Huddle Ventures as a major investor and additional participation from GVFL, Java Capital, IIMA Ventures, Point One Capital and several angel investors. The thermal imaging satellite startup said it has already secured over $25 million in letters of intent from potential clients.
Following closely, PierSight announced a $2 million (Rs 17 crore) funding round from Crescent Enterprises Ventures, Sustainable Ocean Alliance and Seabird Ventures, bringing its total investment to $8 million — among the largest initial investments for Indian spacetech startups.
The synthetic aperture radar (SAR) company had its payload aboard ISRO's PSLV C60 SpaDeX mission earlier this year. The third player, Orbitt Space, launched in 2025 by former Isro scientists Christopher Parmar and Anupam Kumar, is currently in the process of raising funds for its ultra-low Earth orbit (ULEO) satellite propulsion technology.
These three spacetech startups are connected by two factors, besides being based in Ahmedabad — they all have co-founders with experience from Isro's Space Applications Centre (SAC) in the city and they are incubated at IIMA Ventures.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
5 Books Warren Buffett Wants You to Read In 2025
Blinkist: Warren Buffett's Reading List
Undo
Notably, Ahmedabad has one of the two centres for Indian National Space Promotion and Authorization Centre (IN-SPACe) supporting commercial space activities.
Experts said that while the money part is crucial for the founders who often take a leap of faith with their ideas, the important outcome is the emergence of the city as a vital spacetech hub with a conducive ecosystem.
SatLeo founders said that the funds will be utilized to advance the development of its proprietary thermal imaging payload, conduct critical feasibility studies and secure regulatory approvals.
Additionally, the capital will support team expansion, infrastructure setup and pilot testing, enabling the startup to validate its technology and strengthen industry partnerships. The firm's chief technology officer (CTO), Dr Ranendu Ghosh, is a former Isro engineer and former dean at DAIICT.
"Thermal imagery from space is still vastly underutilized and its commercial applications are only set to grow in ways we may not yet fully grasp.
We are backing them for a genuine tech breakthrough that makes thermal data more useful, accessible and affordable," said Sheetal Bahl, partner at Merak Ventures.
For PierSight, the current round of investments takes the total investment to $8 million (Rs 68 crore), making them among the Indian spacetech startups with some of the biggest initial investment. The startup is pioneering use of synthetic aperture radar (SAR) for ocean surveillance including keeping track of vessels, illegal activities, oil spills or even under-sea pipelines and internet cables.
In a post, the founders explained that the investments have helped them make new connections with those on the frontline of space and ocean intersection. The Sustainable Ocean Alliance and venture arm Seabird Ventures is backing the startups tackling oceans' biggest challenges globally, whereas CE Ventures is part of the conglomerate operating some of the largest ports in Middle East.
Gaurav Seth, CEO and co-founder of PierSight who worked at Isro for eight years on technologies such as ground-penetrating radar and synthetic aperture radar (GPR/SAR), said that the recognition at national and global level helps the city in finding its feet as a spacetech hub.
"It is a close-knit community that supports each other. Thus, be it SatLeo or Orbitt, everyone gets the benefit of experience and extensive network. If we scale up, it will also help the peripheral industries and suppliers. The investment and support will go a long way," he said.
PierSight's co-founder and CTO Vinit Bansal is an application engineer who worked with a prominent supplier to Isro.
Orbitt Space is the latest entrant in the spacetech startup ecosystem in the city.
Its co-founder, Parmar, a native of Anand, Gujarat, interned at Isro for a year and then got selected as scientist/engineer afterwards. In his eight-year stint, he worked in verticals such as geocommunication, navigation and opto-quantum communication, satellite payload power systems among others. Kumar, his friend and co-founder, is also an experienced hand with years of satellite testing experience at Isro in Bengaluru and Ahmedabad.
"We are pioneering propulsion system technology that will extend satellite lifetimes significantly and unlock the enormous potential of ULEO for applications that demand high-resolution imaging and enhanced data capabilities. It is a cutting-edge technology and is in different stages of development in other countries across the globe," said Parmar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
28 minutes ago
- India.com
Meet India's Deadliest Hypersonic Missile: Too Fast For Radars, Built To Smash Pakistan And China
New Delhi: India is preparing to test its most advanced hypersonic missile – Extended Trajectory - Long Duration Hypersonic Cruise Missile (E T-LDHCM). Developed entirely with indigenous technology under DRDO's secretive 'Project Vishnu', this missile is being touted as a strategic gamechanger capable of shifting power equations across Asia. The ET-LDHCM will give India the ability to strike deep inside enemy territory, be it Pakistan or China, within minutes and with devastating precision once it becomes operational. With a top speed of Mach 8, roughly 11,000 km/h or eight times the speed of sound, the missile can cover a distance of three kilometres in one second. This speed makes it nearly impossible for existing radar and air defense systems to intercept it. The ET-LDHCM is armed with a range of more than 1,500 kilometres and has the capacity to target and obliterate enemy installations with either nuclear or conventional payloads weighing between 1,000-2,000 kilogrammes. Its scramjet engine, an advanced propulsion system – which takes in air from the atmosphere to burn fuel, enables it to maintain hypersonic speeds for extended periods. It makes it lethal. The DRDO has already successfully conducted a ground test of the engine for a staggering 1,000 seconds. It shows India is not far from deploying this next-gen technology in real-world scenarios. Built for Stealth, Power and Versatility Different from ballistic missiles that follow predictable paths, the ET-LDHCM flies at low altitudes, can manoeuvre mid-flight and is constructed with heat-resistant materials that are capable of withstanding up to 2,000 degree Celsius. It also features oxidation-resistant coatings that ensure it remains functional in even the harshest environments – including saltwater and scorching sunlight. The ET-LDHCM's versatility sets it apart. It can be launched from land, air or sea, giving India unprecedented strategic flexibility. Whether targeting enemy radar stations, naval destroyers or strategic command centres, the missile's precision, range and evasion capabilities make it a nightmare for any adversary. Strategic Significance for India With the ET-LDHCM, India joins an elite club of nations, including the United States, Russia and China, that have mastered hypersonic missile technology. But what makes India's feat more significant is that the missile is a completely Make in India project, designed and built at the Dr. A.P.J. Abdul Kalam Missile Complex in Hyderabad in partnership with private Indian defense firms. This missile provides India with a clear tactical and strategic edge over Pakistan and China. The two nations continue to conduct aggressive missile tests and border provocations. It gives Indian forces the ability to execute surgical hypersonic strikes deep within enemy territory, potentially before the enemy even realises they have been hit. Moreover, beyond military use, mastering hypersonic technologies could boost India's capabilities in satellite launches, aerospace development and disaster response – all critical sectors for national growth. The programme also promises to create thousands of jobs and provide fresh opportunities for Indian MSMEs in the defense ecosystem. When and Where It Will Matter Whether it is a land-attack mission to destroy hardened military bunkers, a naval strike against aircraft carriers and destroyers or a deep strategic assault on enemy infrastructure, the ET-LDHCM is built to deliver lethal blows with incredible speed and minimal warning. In the new age of warfare, where milliseconds can decide outcomes, India's ET-LDHCM could very well be the silent supersonic sword that redefines deterrence and defense.
Time of India
29 minutes ago
- Time of India
Diversification, policy reforms aid Odisha's industrial progress: CM
1 2 3 4 Bhubaneswar: Ahead of the BJP govt's one-year anniversary, chief minister Mohan Charan Majhi on Sunday said that Odisha is becoming a "diversified industrial powerhouse" and a top investment destination in the country by not just approving investments worth Rs 4.5 lakh crore but also successfully grounding projects worth Rs 1.78 lakh crore. "Odisha is no longer just a minerals and metals hub. We are becoming a diversified industrial powerhouse, where opportunity flows from port to plant, and from cities to every aspirational district," the CM said during a meeting with leading industrialists and entrepreneurs in the city. "We are not merely sanctioning projects; we are grounding them. We are not making promises; we are delivering results — at scale, with speed, and with purpose," Majhi said. Mapping the industrial growth story, he said, "In just one year, we approved over 200 large and mega projects. Odisha now stands for credibility, competitiveness and commitment to progress." The CM said industries are diversifying from minerals and metals to green energy, agro-processing, technical textiles and shipbuilding, with investments flowing into 20 sectors. He attributed the success to proactive policy push like outcome-based governance and a "whole-of-govt model" that emphasises seamless coordination between departments and agencies. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 오스템 임플란트 받아가세요 임플란터 더 알아보기 Undo Roadshows in Delhi, Mumbai and Singapore have pitched Odisha as a hub for chemical, electronics, capital goods and advanced manufacturing, while two major events, Pravasi Bharatiya Divas and Utkarsh Odisha — Make in Odisha Conclave-2025, attracted global attention and industrial giants expanding the state's economic footprint, Majhi said. Majhi also spoke about the ambitious vision for 'Samruddha Odisha' by 2036, aligning with the centenary celebration of formation of the state. He outlined four key priorities in the upcoming year, including the launch of new policies targeting emerging and sunrise sectors, expansion of land banks, logistics corridors and critical infrastructure. He emphasised revamping the single-window system with digital-first project tracking and simplification of regulatory compliances to speed up approvals and encourage entrepreneurship. To support industrial labour, the state is developing 13 workers' hostels and modernising seven industrial estates with plug-and-play infrastructure. Furthermore, 30 MSME parks and 8 new industrial areas have been initiated to empower small enterprises and entrepreneurs. Industries minister Sampad Chandra Swain, MSME minister Gokulananda Mallik, development commissioner Anu Garg, and senior officers, among others, attended the event.
Time of India
29 minutes ago
- Time of India
Are antibiotics losing battle against typhoid?
1 2 3 Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India. Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India.
